

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) A PYY agonist derivative of the formula:

$(X)_n - Z$

wherein X is a ~~radical~~ 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenyl-methoxycarbonyl (FMS), Z is the residue of a PYY agonist linked to the radical X through an amino or hydroxyl group, and n is 1 to 3, or a pharmaceutically acceptable salt thereof.

2. (currently amended) A PYY agonist derivative of claim 1, wherein the PYY agonist is PYY of the sequence represented by †SEQ ID NO.: 1†:

YPIKPEAPGEDASPEELNRYYASLRHYLNLVTRQRY-NH₂.

3. (currently amended) A PYY agonist derivative of claim 1, wherein the PYY agonist is PYY₃₋₃₆ of the sequence represented by {SEQ ID NO.: 2}:

IKPEAPGEDASPEELNRYYASLRHYLNLVTRQRY-NH₂.

4. (original) The PYY agonist derivative of claim 1 selected from the group consisting of the derivatives herein designated Fmoc-PYY, (Fmoc)₂-PYY, (Fmoc)₃-PYY, FMS-PYY, (FMS)₂-PYY and (FMS)₃-PYY.

5. (original) The PYY agonist derivative of claim 1 selected from the group consisting of the derivatives herein designated Fmoc-PYY₃₋₃₆, (Fmoc)₂-PYY₃₋₃₆, (Fmoc)₃-PYY₃₋₃₆, FMS-PYY₃₋₃₆, (FMS)₂-PYY₃₋₃₆, and (FMS)₃-PYY₃₋₃₆.

6. (currently amended) The PYY agonist derivative herein designated (FMS)₂-PYY₃₋₃₆, of the sequence represented by {SEQ ID NO.: 3}.

7. (currently amended) A pharmaceutical composition comprising a PYY agonist derivative according to ~~any one of claims claim 1 to 6~~, and a pharmaceutically acceptable carrier.

8. (original) A pharmaceutical composition comprising (FMS)₂-PYY₃₋₃₆ and a pharmaceutically acceptable carrier.

Claims 9-16 (Cancelled)

17. (original) A method for reduction of food intake which comprises administering to an individual in need an effective amount of a PYY agonist derivative of claim 1.

18. (original) A method for treatment of a disease, condition or disorder that can be alleviated by reduction of food intake which comprises administering to an individual in need an effective amount of a PYY agonist derivative of claim 1.

19. (currently amended) The method according to
claim 14 18 wherein said disease or disorder is obesity.

20. (currently amended) The method according to
claim 14 18 wherein said disease or disorder is hypertension,
dyslipidemia, cardiovascular risk, eating disorder, insulin-
resistance, or diabetes mellitus.

21. (original) A method of treating obesity in an
individual comprising administering to said individual a
therapeutically effective amount of $(FMS)_2-PYY_{3-36}$, or a
pharmaceutically acceptable salt thereof.

22. (original) A method of inducing weight loss in
an individual comprising administering to said individual a
therapeutically effective amount of a PYY agonist derivative
of claim 1 or a pharmaceutically acceptable salt of said
compound.

23. (currently amended) A method according to claim
22 of inducing weight loss in an individual comprising

~~administering to said individual a therapeutically effective amount of wherein said PYY agonist derivative is~~
~~(FMS)₂-PYY₃₋₃₆, or a pharmaceutically acceptable salt thereof.~~